The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Volkow, N. D.
* Articles by Pappas, N.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Volkow, N. D.
* Articles by Pappas, N.
Related Collections
* Neurotransmitters
* Attention Deficit Hyperactivity Disorder
* Other Somatic Therapy
* PET
Am J Psychiatry 155:1325-1331, October 1998
©Copyright 1998 American Psychiatric Association


Regular Article

Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate

Nora D. Volkow, M.D., Gene.-Jack Wang, M.D., Joanna S. Fowler, Ph.D., Samuel J. Gatley, Ph.D., Jean Logan, Ph.D., Yu-Shin Ding, Ph.D., Robert Hitzemann, Ph.D., and Naomi Pappas, M.S.

Objective:The therapeutic effects of methylphenidate in the treatment of attention deficit disorder have been attributed to its ability to increase the synaptic concentration of dopamine by blocking the dopamine transporters. However, the levels of dopamine transporter blockade achieved by therapeutic doses of methylphenidate are not known. This study measured, for the first time, dopamine transporter occupancy by orally administered methylphenidate in the human brain and its rate of uptake in the brain. Method:Positron emission tomography (PET) and [11C]cocaine were used to estimate dopamine transporter occupancies after different doses of oral methylphenidate in seven normal subjects (mean age=24 years, SD=7). In addition, the pharmacokinetics of oral methylphenidate were measured in the baboon brain through use of PET and [11C]methylphenidate administered through an orogastric tube.Results:At 120 minutes after administration, oral methylphenidate produced a dose-dependent blockade of dopamine transporter; means=12% (SD=4%) for 5 mg, 40% (SD=12%) for 10 mg, 54% (SD=5%) for 20 mg, 72% (SD=3%) for 40 mg, and 74% (SD=2%) for 60 mg. The estimated dose of oral methylphenidate required to block 50% of the dopamine transporter corresponded to 0.25 mg/kg. Oral methylphenidate did not reach peak concentration in brain until 60 minutes after its administration.Conclusions:Oral methylphenidate is very effective in blocking dopamine transporters, and at the weight-adjusted doses used therapeutically (0.3 to 0.6 mg/kg), it is likely to occupy more than 50% of the dopamine transporters. The time to reach peak brain uptake for oral methylphenidate in brain corresponds well with the reported time course to reach peak behavioral effects. Am J Psychiatry 1998; 155: 1325-1331




This article has been cited by other articles:


Home page
J Atten DisordHome page
A. D. Mahon, B. R. Stephens, and A. S. Cole
Exercise Responses in Boys With Attention Deficit/Hyperactivity Disorder: Effects of Stimulant Medication
J Atten Disord, September 1, 2008; 12(2): 170 - 176.
[Abstract] [PDF]


Home page
J. Neurosci.Home page
C. M. Dodds, U. Muller, L. Clark, A. van Loon, R. Cools, and T. W. Robbins
Methylphenidate Has Differential Effects on Blood Oxygenation Level-Dependent Signal Related to Cognitive Subprocesses of Reversal Learning
J. Neurosci., June 4, 2008; 28(23): 5976 - 5982.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
N. D. Volkow, G.-J. Wang, F. Telang, J. S. Fowler, J. Logan, M. Jayne, Y. Ma, K. Pradhan, and C. Wong
Profound Decreases in Dopamine Release in Striatum in Detoxified Alcoholics: Possible Orbitofrontal Involvement
J. Neurosci., November 14, 2007; 27(46): 12700 - 12706.
[Abstract] [Full Text] [PDF]


Home page
Cereb CortexHome page
A. Diamond
Consequences of Variations in Genes that affect Dopamine in Prefrontal Cortex
Cereb Cortex, September 1, 2007; 17(suppl_1): i161 - i170.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
G. S Goldfield, C. Lorello, and E. Doucet
Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food?
Am. J. Clinical Nutrition, August 1, 2007; 86(2): 308 - 315.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
N. D. Volkow, G.-J. Wang, J. Newcorn, F. Telang, M. V. Solanto, J. S. Fowler, J. Logan, Y. Ma, K. Schulz, K. Pradhan, et al.
Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults With Attention-Deficit/Hyperactivity Disorder
Arch Gen Psychiatry, August 1, 2007; 64(8): 932 - 940.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. D. Gray, M. Punsoni, N. E. Tabori, J. T. Melton, V. Fanslow, M. J. Ward, B. Zupan, D. Menzer, J. Rice, C. T. Drake, et al.
Methylphenidate Administration to Juvenile Rats Alters Brain Areas Involved in Cognition, Motivated Behaviors, Appetite, and Stress
J. Neurosci., July 4, 2007; 27(27): 7196 - 7207.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
R.R. Horsley and H. J. Cassaday
Methylphenidate can reduce selectivity in associative learning in an aversive trace conditioning task
J Psychopharmacol, July 1, 2007; 21(5): 492 - 500.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
D. Nutt, K. Demyttenaere, Z. Janka, T. Aarre, M. Bourin, P. L. Canonico, J. L. Carrasco, and S. Stahl
The other face of depression, reduced positive affect: the role of catecholamines in causation and cure
J Psychopharmacol, July 1, 2007; 21(5): 461 - 471.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
D Devos, P Krystkowiak, F Clement, K Dujardin, O Cottencin, N Waucquier, K Ajebbar, B Thielemans, M Kroumova, A Duhamel, et al.
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 470 - 475.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. G. Nutt, J. H. Carter, and N. E. Carlson
Effects of Methylphenidate on Response to Oral Levodopa: A Double-blind Clinical Trial
Arch Neurol, March 1, 2007; 64(3): 319 - 323.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al.
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology
J Psychopharmacol, January 1, 2007; 21(1): 10 - 41.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
H. Ashton, P. Gallagher, and B. Moore
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder
J Psychopharmacol, September 1, 2006; 20(5): 602 - 610.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
T. E. Wilens and J. Biederman
Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth
J Psychopharmacol, July 1, 2006; 20(4): 580 - 588.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
B.J. Casey and S. Durston, Ph.d.
From Behavior to Cognition to the Brain and Back: What Have We Learned From Functional Imaging Studies of Attention Deficit Hyperactivity Disorder?
Am J Psychiatry, June 1, 2006; 163(6): 957 - 960.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
T. J. Spencer, J. Biederman, P. E. Ciccone, B. K. Madras, D. D. Dougherty, A. A. Bonab, E. Livni, D. A. Parasrampuria, and A. J. Fischman
PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate
Am J Psychiatry, March 1, 2006; 163(3): 387 - 395.
[Abstract] [Full Text] [PDF]


Home page
AM J HOSP PALLIAT CAREHome page
A. Sood, D. L. Barton, and C. L. Loprinzi
Use of methylphenidate in patients with cancer
American Journal of Hospice and Palliative Medicine, January 1, 2006; 23(1): 35 - 40.
[Abstract] [PDF]


Home page
FocusHome page
L. L. Greenhill, S. Pliszka, M. K. Dulcan, W. Bernet, V. Arnold, J. Beitchman, R. S. Benson, O. Bukstein, J. Kinlan, J. McClellan, et al.
Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults
Focus, October 1, 2004; 2(4): 642 - 668.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
T. E. Wilens, S. V. Faraone, and J. Biederman
Attention-Deficit/Hyperactivity Disorder in Adults
JAMA, August 4, 2004; 292(5): 619 - 623.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
N. D. Volkow, G.-J. Wang, J. S. Fowler, F. Telang, L. Maynard, J. Logan, S. J. Gatley, N. Pappas, C. Wong, P. Vaska, et al.
Evidence That Methylphenidate Enhances the Saliency of a Mathematical Task by Increasing Dopamine in the Human Brain
Am J Psychiatry, July 1, 2004; 161(7): 1173 - 1180.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
N. D. Volkow and J. M. Swanson
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Am J Psychiatry, November 1, 2003; 160(11): 1909 - 1918.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. Kuczenski and D. S. Segal
Exposure of Adolescent Rats to Oral Methylphenidate: Preferential Effects on Extracellular Norepinephrine and Absence of Sensitization and Cross-Sensitization to Methamphetamine
J. Neurosci., August 15, 2002; 22(16): 7264 - 7271.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Rozans, A. Dreisbach, J. J.L. Lertora, and M. J. Kahn
Palliative Uses of Methylphenidate in Patients With Cancer: A Review
J. Clin. Oncol., January 1, 2002; 20(1): 335 - 339.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. R. Gerasimov, M. Franceschi, N. D. Volkow, A. Gifford, S. J. Gatley, D. Marsteller, P. E. Molina, and S. L. Dewey
Comparison between Intraperitoneal and Oral Methylphenidate Administration: A Microdialysis and Locomotor Activity Study
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 51 - 57.
[Abstract] [Full Text]


Home page
ScienceHome page
N. D. Volkow, S. J. Gatley, J. S. Fowler, G. Wang, J. Swanson;, R. R. Gainetdinov, W. C. Wetsel, and M. G. Caron;
Serotonin and the Therapeutic Effects of Ritalin
Science, April 7, 2000; 288(5463): 11a - 11.
[Full Text]


Home page
Psychiatr. Serv.Home page
R. Castaneda, R. Levy, M. Hardy, and M. Trujillo
Alcohol & Drug Abuse: Long-Acting Stimulants for the Treatment of Attention-Deficit Disorder in Cocaine-Dependent Adults
Psychiatr Serv, February 1, 2000; 51(2): 169 - 171.
[Full Text] [PDF]


Home page
JWatch PsychiatryHome page
ADHD: Unanswered Questions and Controversies
Journal Watch Psychiatry, November 1, 1999; 1999(1101): 17 - 17.
[Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
N. D. Volkow, G.-J. Wang, J. S. Fowler, S. J. Gatley, J. Logan, Y.-S. Ding, S. L. Dewey, R. Hitzemann, A. N. Gifford, and N. R. Pappas
Blockade of Striatal Dopamine Transporters by Intravenous Methylphenidate Is Not Sufficient to Induce Self-Reports of "High"
J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 14 - 20.
[Abstract] [Full Text]


Home page
JWatch PsychiatryHome page
Rate and Level of Dopamine Blockade Achieved by MPH
Journal Watch Psychiatry, December 1, 1998; 1998(1201): 2 - 2.
[Full Text]


Home page
J. Neurosci.Home page
N. D. Volkow, G.-J. Wang, J. S. Fowler, J. Logan, M. Gerasimov, L. Maynard, Y.-S. Ding, S. J. Gatley, A. Gifford, and D. Franceschi
Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain
J. Neurosci., January 15, 2001; 21(2): RC121 - RC121.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org